TWI803730B - A use of manufacturing a composition for improving the immunity - Google Patents

Abstract

The present invention provides a use of manufacturing a composition for improving the immunity, wherein the composition comprises the mycelium ofLactobacillus or the active substance thereof and theLactobacillus is selected from the group consisting ofBifidobacterium lactis ,Lactobacillus rhamnosus ,Lactobacillus plantarum , andLactobacillus fermentum or the combination thereof.

Description

Use for preparing composition for improving immunity

This disclosure relates to the use of a composition for improving immunity; more specifically, the composition contains an active substance of lactic acid bacteria, wherein the lactic acid bacteria are selected from the group consisting of Bifidobacterium lactis , rhamnose lactis One or a combination of the group consisting of Lactobacillus rhamnosus, Lactobacillus plantarum or Lactobacillus fermentum . By administering the composition to the mother, the immunity of the offspring is enhanced.

immune response and antibodies

When a specific foreign pathogen (antigen) invades the human body, the human body has a series of defense mechanisms to resist the foreign substance, that is, the immune response. B cells, which are immune cells in the human body, produce antibodies after being stimulated by antigens. The so-called antibody is a kind of glycoprotein, also known as immunoglobulin (Immunoglobulin, Ig). Antibodies can combine with antigens to achieve the effect of preventing foreign substances from further invading the human body in the immune response. There are five types of immunoglobulins in mammals: IgM, IgG, IgA, IgE, and IgD.

Immunoglobulins in adult individuals

Immunoglobulin IgM is a low-affinity antibody that is mainly involved in the primary immune response. In other words, IgM, like the vanguard, is the first antibody produced after stimulation, effectively fending off foreign pathogens in the early immune response. Next, IgG, which is the main circulating immunoglobulin in the human body, is a high-affinity antibody. IgG will be produced in large quantities and can be maintained for a long time, which can help the human body shorten the time of immune response when encountering the second invasion of the same pathogen. That is, IgG provides long-term immune protection. In addition, secretory immunoglobulin IgA mainly acts on the mucosal immune system of the human body, such as the digestive tract, respiratory tract, and genitourinary system. When foreign pathogens invade the human body and stimulate the local immune system, IgA will participate in the immune response of the mucosal system for a short time. Immunoglobulin IgE is a kind of cytophilic antibody, which is related to immunity such as respiratory tract, parasites, and skin allergies. Immunoglobulin IgD is less abundant in the human body, and current studies have pointed out that this antibody is related to autoantibodies and antiviral antibodies.

Immunoglobulins in fetuses, infants, etc.

Because of the amniotic membrane barrier in the mother's body, the offspring will not be affected by foreign pathogens, and there will be no subsequent immune response. However, after birth, the offspring come into contact with pathogens from the outside world. At this time, the daughter body itself will not synthesize immunoglobulins to resist foreign pathogens. Therefore, the key to the immunity of offspring in infants, newborns, and early childhood lies in the mother. Specifically, daughters mostly acquire antibodies through their mothers. Generally speaking, daughters can synthesize antibody IgG by themselves within 3 months after birth. Daughters do not have IgG concentrations close to those of adults until pre-childhood at about 3 to 5 years of age. Immunoglobulin IgG is the only antibody that can cross the placenta and provide immunity to offspring during fetal life. In addition to IgG, another immunoglobulin IgA is related to the immunity of the daughter. Antibody IgA generally begins to be synthesized by itself 4 to 6 months after birth. After the progeny is about one year old in early childhood, its IgA concentration can reach 25% of the IgA concentration in the adult special body. Although IgA cannot cross the placenta, it is present in large quantities in the mother's breast milk. Therefore, the daughter can obtain IgA from the mother through the process of breastfeeding the daughter. In this way, the effect of enhancing the immunity of the offspring can be achieved, and the infection of the respiratory tract and intestinal tract can be effectively avoided. As mentioned above, the immune mechanism of offspring in fetuses, newborns, infants and young children is different from that of adults. The immunity of offspring is mostly obtained from the mother through supplementation.

Probiotics and Immunity

Probiotics are known to have various effects on the human body, such as improving the gastrointestinal tract, regulating allergies, protecting the liver, and enhancing muscle strength. Many literatures also pointed out that probiotics can be used to improve immunity. Studies have found that probiotics can promote the toxicity of natural killer cells and the phagocytosis of macrophages, and enhance non-specific immune responses. In addition, probiotics can also regulate the expression of intestinal Th1, Th2, Treg and other cells to achieve anti-inflammatory or pro-inflammatory effects.

Since the immunity of the offspring depends on the immunoglobulins provided by the mother, there is still a need to develop lactic acid bacteria strains supplemented by the mother during pregnancy and lactation in order to enhance the immunity of the offspring.

The present disclosure provides a use for preparing a composition for improving immunity, wherein the composition comprises a lactic acid bacterium cell or its active substance, wherein the lactic acid bacterium is selected from Bifidobacterium lactis , Lactobacillus rhamnosus One or a combination of the group consisting of Lactobacillus rhamnosus , Lactobacillus plantarum and Lactobacillus fermentum .

Preferably, the Bifidobacterium lactis GKK2 is BCRC 910826, Lactobacillus rhamnosus GKLC1 is BCRC 910828, Lactobacillus plantarum GKM3 is BCRC 910787, or Lactobacillus fermentum GKF3 is BCRC 910824, deposited in the Food Industry Development Research Foundation Institute of Biological Resources Research Center.

Preferably, the composition is administered in an effective amount to a mother as the subject.

Preferably, the composition is administered during pregnancy or lactation of the mother.

Preferably, the immunity refers to the immunity of a daughter of the mother.

Preferably, the immunity refers to the immunity of the progeny in fetus, newborn, infant or young child.

Preferably, the immunity refers to the concentration of immunoglobulin in the serum of the progeny.

Preferably, the enhancement of immunity refers to the higher concentration of immunoglobulin in the serum of offspring whose mothers are given the composition compared to offspring whose mothers are not given the composition.

Preferably, the immunoglobulin (Ig) is IgG or IgA.

Preferably, the active substances of the lactic acid bacteria are prepared by the following method:

(a) taking the lactic acid bacteria and inoculating them in a solid-state medium for solid-state culture to form colonies;

(b) inoculating the colony cultured in step (a) into a liquid medium for liquid culture to obtain a liquid medium containing bacteria;

(c) Inoculate the liquid culture medium containing bacteria in step (b) into the fermentation tank for liquid amplification to obtain the bacteria liquid;

(d) centrifuging the bacterial liquid in step (c) to obtain bacterial sludge;

(e) freeze-drying the fungus slime in step (d) as fungus powder; and

(f) Extracting the bacterial powder in step (e) with an alcohol as a solvent to obtain an alcohol extract.

Preferably, the freeze-drying temperature is -196 to -40°C.

Preferably, the alcohols are methanol, ethanol, isopropanol or combinations thereof.

Preferably, the amount of the alcohol added is about 9 to 11 times the volume of the bacterial powder.

Preferably, the extraction is ultrasonic vibration extraction for about 0.5 to 1.5 hours.

Preferably, the composition comprises an additive selected from the group consisting of excipients, preservatives, diluents, fillers, absorption enhancers, sweeteners or combinations thereof.

Preferably, the composition is a medicine, feed, beverage, nutritional supplement, dairy product, food or health food.

Preferably, the form of the composition is powder, lozenge, suppository, microcapsule, ampoule, liquid spray or suppository.

"Immunity" as used herein refers to a protective response in which an organism recognizes and eliminates antigenic substances. In a specific aspect, immunity refers to the concentration of immunoglobulins in the serum of the organism.

The "bacteria" mentioned herein refers to the structure of the lactic acid bacteria used in the present disclosure in various culture stages. In a specific aspect, the bacterial system refers to a complete or partial structure of lactic acid bacteria. In a specific aspect, the bacterial system refers to the colonies of lactic acid bacteria groups formed by the division and reproduction of a single bacterium. In a specific aspect, the culture stage refers to liquid culture or liquid scale-up of inoculation in a fermenter.

The "active substance" mentioned in this article refers to the substance selected from the lactic acid bacteria cells used in this disclosure after being processed through specific experimental steps, or the mixture of the cells and the culture medium or culture solution. In a specific aspect, the active substance refers to the centrifuged bacteria sludge, freeze-dried bacteria powder or solvent-extracted extract. In a specific aspect, the active substance refers to a solid medium containing bacteria, a liquid medium containing bacteria, or a liquid amplified bacteria solution in a fermentation tank.

The "effective amount" mentioned herein refers to an amount used, which is sufficient to produce the aforementioned effect of enhancing immunity.

The "pregnancy" mentioned in this article is also called pregnancy, which refers to the process of embryo or fetus growing up in the body of a mammalian female.

"Breastfeeding" mentioned in this article is also called breastfeeding, breastfeeding, breastfeeding or breastfeeding. Breastfeeding refers to the behavior of a female mother feeding her daughter's breastmilk with her breast.

As used herein, "fetus" refers to a human individual from the eighth week after the formation of a fertilized egg until delivery.

As used herein, "neonatal" refers to a human individual from 0 to 5 weeks of age.

As used herein, "infant" refers to a human individual from 5 weeks to 1 year old.

As used herein, "young child" refers to a human subject aged 1-3 years.

In the fetal period before the mother's delivery, and in the newborn, infant, and young child period after the mother's delivery, the immunity of the daughter is not as good as that of a human adult. This is because autosynthesis of immunoglobulins begins after a certain period of time after birth, so daughters need to obtain immunoglobulins from their mothers.

In order to improve the immunity of the daughter body, the present disclosure develops a composition comprising a lactic acid bacteria cell and its active substance. The composition is administered to the mother, and the immunoglobulin is given to the daughter through the mother's placenta or breastfeeding, so as to achieve the effect of increasing the concentration of the immunoglobulin in the daughter. In a preferred embodiment, the lactic acid bacteria contained in the composition are selected from Bifidobacterium lactis , Lactobacillus rhamnosus , Lactobacillus plantarum or fermented milk One or a combination of the group consisting of Lactobacillus fermentum . In a preferred implementation, the above-mentioned lactic acid bacteria are GKK2 (BCRC 910826), GKLC1 (BCRC 910828, GKM3 (BCRC 910787) or GKF3 (BCRC 910824).

Regarding the culture of bacteria, lactic acid bacteria are inoculated on a solid-state medium for solid-state culture to activate the bacteria and form colony formation. In a preferred embodiment, the temperature of the solid-state culture is 30 to 55°C, more preferably 32 to 45°C. In a preferred embodiment, the solid-state culture lasts from 0.5 to 3 days, more preferably from 1 to 2.5 days. In a preferred embodiment, the solid medium is MRS agar. After the colony growth on the solid medium is completed, a single colony is picked up and inoculated into a test tube containing MRS liquid medium, and activated by liquid culture. In a preferred embodiment, the temperature of MRS liquid culture is 30 to 55°C, more preferably 32 to 45°C. In a preferred embodiment, the time for MRS liquid culture is 14 to 18 hours, more preferably 16 hours. The bacteria in the MRS liquid culture medium were inoculated into Erlenmeyer flasks containing 1L of liquid culture medium. In a preferred embodiment, the pH value of the liquid culture is from pH 5.0 to 7.0, more preferably from pH 5.5 to 6.5. In a preferred embodiment, the formulation of the liquid medium is shown in Table 1 below. After the growth of the bacterium in the liquid medium is completed, the bacterium and the liquid medium are inoculated in a fermenter for liquid amplification to obtain a bacterium-containing liquid. In a preferred embodiment, the temperature of the fermenter culture is 30 to 55°C, more preferably 32 to 45°C. In a preferred embodiment, the time for culturing in the fermenter is 16 to 20 hours, more preferably 17 to 19 hours.

Table 1 Element Ratio (weight percent) carbon source 0 to 10% soy milk 0.1~5% nitrogen source 0.1~5% ion 0.01~2% water The remaining part

Regarding the preparation of bacterial powder, after the growth of the bacterial cells in liquid culture is completed, the bacterial liquid containing the liquid culture medium containing the bacterial cells is collected. Next, the bacterial liquid is centrifuged to remove the liquid medium used for fermentation to obtain the bacterial sludge. In a preferred embodiment, the centrifugation speed of the liquid medium containing the bacteria is 1000 to 15000 rpm. The obtained bacteria slime is mixed with the protective agent and then freeze-dried to obtain the bacteria powder, which is stored at low temperature after freeze-drying. In a preferred embodiment, the protective agent is 6 to 30% skimmed milk powder. In a preferred embodiment, the storage temperature is 0°C to 8°C, more preferably 2°C to 6°C. The preserved bacterial powder was used as a test substance in the following animal experiments.

The present disclosure comprises a composition of lactic acid bacteria cells and active substances thereof, and further comprises additives. In a preferred embodiment, the additive can be excipient, preservative, diluent, filler, absorption enhancer, sweetener, or a combination thereof. The excipient may be selected from sodium citrate, calcium carbonate, calcium phosphate, sucrose or combinations thereof. The preservatives can prolong the shelf life of the pharmaceutical composition, eg benzyl alcohol, parabens. The diluent may be selected from water, ethanol, propylene glycol, glycerin or combinations thereof. Fillers may be selected from lactose, galactose, high molecular weight glycols or combinations thereof. The absorption enhancer may be selected from dimethylsulfoxide (DMSO), laurocapram, propylene glycol, glycerin, polyethylene glycol, or combinations thereof. The sweetener may be selected from Acesulfame K, aspartame, saccharin, sucralose/sucralose, neotame or combinations thereof. In addition to the above-listed additives, other suitable additives can be selected as required, provided that the medicinal effect of the composition is not affected.

The composition can be developed into various commercial products in the field of medicine. In a preferred embodiment, the composition is a medicine, feed, beverage, nutritional supplement, dairy product, food or health food.

Under the premise of not affecting the effect of the bacteria or active substances, the composition of the present disclosure can be made into any pharmaceutical form according to the needs of the recipient. In a preferred embodiment, the composition is in the form of powder, lozenge, suppository, microcapsule, ampoule/ampule, liquid spray or suppository.

According to the form of the composition of the present disclosure, an appropriate dose of the composition is administered to a subject at a predetermined time point by an applicable route. In a preferred embodiment, the route of administration includes oral or parenteral, intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, respiratory (aerosol), rectal, vaginal or topical (including oral and sublingual). In a preferred embodiment, the predetermined time point includes every meal, every day, and every week. In a preferred embodiment, the subject is human or animal. In a preferred embodiment, the mother who is the subject provides the immunoglobulin to the offspring through the placenta or breastfeeding, so the subject is a mother who is pregnant or breastfeeding.

Effective amount For in vitro cell culture experiments, the total volume of cell culture medium used in each culture is defined as "μg/ml". In animal experiments, the effective dose is defined as "g/60 kg body weight/day". Through the following calculation formula, the effective dose obtained from the in vitro cell culture experiment can be converted into the effective dose for animals, and the effective dose for animals can be converted into the effective dose for humans according to the metabolic rate. I. In general (Reagan-Shaw et al ., 2008), 1 "μg/ml" unit (based on the effective dose obtained from in vitro cell culture experiments) can be equivalent to 1 "mg/kg body weight/day" unit ( Based on the effective amount obtained from rat model experiments). Based on the fact that the metabolic rate of rats is 6.2 times that of humans, the effective dosage for humans can be further obtained. II. If the effective dose is 500 μg/ml based on in vitro cell culture experiments, the effective dose used in rats can be calculated as 500 mg/kg body weight/day (ie, 0.5 g/kg body weight/day ). Further, considering the aforementioned difference in metabolic rate, the effective dose for human use can be calculated as about 5 g/60 kg body weight/day. III. According to the following test results, the effective dose based on the rat test is 2000 mg/kg body weight/day, and the effective dose for humans is calculated to be about 20 g/60 kg body weight/day through the above conversion formula.

In a preferred embodiment, the effective amount of lactic acid bacteria cells or active substances contained in the composition is 2 g to 40 g/60 kg body weight/day, and more preferably 5 g to 30 g/60 kg body weight/day, more preferably 10 g to 25 g/60 kg body weight/day.

Embodiment one: strain source

The strains used in the preparation of the test substances in the examples of the present disclosure were purchased from the Center for Biological Resource Conservation and Research of the Food Industry Development Institute. The names and registration numbers of these strains are listed in Table 2 below. However, the strains described in this disclosure are not limited to those obtained from such channels, and those with ordinary knowledge in the technical field can also obtain the strains of these lactic acid bacteria from other microbial strain preservation units.

Table 2: Strains serial number name Registration number 1 Bifidobacterium lactis GKK2 ( Bifidobacterium lactis ) BCRC 910826 2 Lactobacillus rhamnosus GKLC1 ( Lactobacillus rhamnosus ) BCRC 910828 3 Lactobacillus plantarum GKM3 ( Lactobacillus plantarum ) BCRC 910787 4 Lactobacillus fermentum GKF3 ( Lactobacillus fermentum ) BCRC 910824

Embodiment two: strain culture

Lactic acid cells were inoculated on MRS agar as a solid medium, and cultured in a solid state at 37°C for 2 days to activate the cells and form colony formation. After the colony growth on MRS agar is completed, inoculate a single colony into a test tube containing MRS liquid medium, culture and activate it at 37°C for 16 hours, and then inoculate it in a 1L liquid medium with a pH value of 6.0 in an Erlenmeyer flask. The formulation of the culture medium is shown in Table 1 above. After the growth of the bacteria in the liquid medium is completed, the bacteria and the liquid medium are inoculated in a fermenter, and cultured at 37° C. for 18 hours for liquid amplification to obtain the bacteria liquid.

Embodiment three: bacteria powder preparation

After the growth of the bacteria in the liquid culture is completed, the bacteria liquid containing the liquid medium containing the bacteria is collected. The bacterial liquid was centrifuged at 6000 rpm to remove the liquid medium and obtain the bacterial sludge. Mix the fungus slime with 15% skimmed milk powder as a protective agent, freeze-dry to obtain the fungus powder, and store the fungus powder at 4°C. The preserved bacterial powder was used as a test substance in the following animal experiments.

Embodiment five: detection of immunoglobulin concentration

experimental animals

A total of 30 pregnant female mice of the S Prague-Dawley (SD) strain were purchased from BioLASCO Taiwan Co., Ltd., Taiwan. The animals were kept in the rat breeding room of the Taiwan-US Experimental Animal Center, and each female mouse was individually kept in a cage. The room temperature was maintained at 22 ± 2°C, the humidity was 40-60%, the ventilation frequency was 10-15 times per hour, and the light and darkness were regularly 12 hours. Feed and sterile reverse osmosis water were allowed to feed freely to the female mice. The new female rats were acclimatized to the environment for 3 days before starting the experiment.

Test design

Thirty pregnant female rats were divided into five groups, a control group and an experimental group of four lactic acid bacteria strains, with 6 female rats in each group. From the 13th day to the 21st day of pregnancy and the 1st day to the 13th day of lactation (that is, the 1st to 13th day after delivery), the mothers in the four experimental groups were given oral tube feeding once a day. Bacteria powders of GKK2, GKLC1, GKM3, and GKF3, and female rats in the control group were given reverse osmosis water as test substances. The dose of the test substance was 2,000 mg/kg B.W. (Body Weight).

Six pups from each group were injected intraperitoneally with OVA/CFA mixture (0.5 μg/pup) as antigen for induction of immune response on day 3 after birth. Pups were sacrificed and blood collected on day 13 after birth. The collected blood samples of young mice were used to measure the concentration of immunoglobulin IgG and IgA in serum of the blood samples with commercially available kits (Mouse IgG ELISA Quantitation Set and Mouse IgA ELISA Quantitation Set, Bethyl).

Data processing and statistical analysis

Experimental data are expressed as mean (mean) and standard deviation (standard deviation, S.D.). The experimental data was analyzed using the Duncan test of One-Way ANOVA in the SPSS statistical software to analyze the differences between the data among the groups, and the p value was less than 0.05 as the significant difference level.

test results

The results of detecting the IgG concentration in the serum of young mice are shown in Figure 2. In the control group given reverse osmosis water during pregnancy, the IgG concentration in the serum of young mice was 224.4. In the experimental group given lactic acid bacteria during pregnancy, the serum IgG concentration of young mice was 3042.3 in the GKK2 group, 3287.7 in the GKLC1 group, 3309 in the GKM3 group, and 2857.7 in the GKF3 group. By comparing the IgG concentrations in the serum of each group, after OVA (ovalbumin) induction, the pups of the mothers that ingested lactic acid bacteria had significantly higher concentrations of immunoglobulin IgG after birth than the pups of mothers that did not ingest lactic acid bacteria ( p > 0.05). Among them, the IgG concentration in the GKM3 group was the highest. These results indicate that maternal intake of lactic acid bacteria during pregnancy, such as GKK2, GKLC1, GKM3 or GKF3, can increase the antibody IgG of the unborn fetus through the placenta, increase the IgG concentration of the offspring after birth, and achieve the effect of enhancing immunity.

The results of detecting the IgA concentration in the serum of young mice are shown in Figure 3. In the control group given reverse osmosis water while breast-feeding, the IgA concentration in the serum of young mice was 1025.9. In the experimental group given lactic acid bacteria to the mother mice while breastfeeding, the IgA concentration in the serum of the young mice was 6106 in the GKK2 group, 6767 in the GKLC1 group, 6854.6 in the GKM3 group, and 3612.7 in the GKF3 group. By comparing the IgA concentrations in the serum of each group, after OVA (ovalbumin) induction, the pups of the mother mice that ingested lactic acid bacteria had significantly higher concentrations of immunoglobulin IgA after birth than the pups of mothers that did not ingest lactic acid bacteria ( p > 0.05). Among them, the concentration of IgA in the GKM3 group was the highest. These results indicate that the intake of lactic acid bacteria such as GKK2, GKLC1, GKM3 or GKF3 by lactating mothers can increase the antibody IgA of the offspring through breast milk through breastfeeding, increase the IgA concentration of the offspring after birth, and enhance immunity Effect.

Embodiment six: composition preparation

If the strains disclosed in the present disclosure are applied to food, the following compositions 1 to 2 are used as illustrative examples.

Composition 1: Take the bacteria powder (20 wt%) of Bifidobacterium lactis BCRC 910826, mix it well with benzyl alcohol (8 wt%) as a preservative, and glycerin (7 wt%) as a diluent, And dissolved in pure water (65 wt%), stored at 4 ° C for use. The aforementioned wt% refers to the ratio of each component to the total weight of the composition.

Composition 2: replace the bacteria powder of Bifidobacterium lactis GKK2 ( Bifidobacterium lactis ) BCRC 910826 in composition 1 with the bacteria powder (20 wt%) of Lactobacillus rhamnosus BCRC 910828, and the remaining composition and combination Object 1 is the same.

If the bacterial species disclosed in the present disclosure is used in a liquid dosage form for medical purposes, the following compositions 3 to 4 are used as illustrative examples.

Composition 3: Take the bacteria powder (20 wt%) of Lactobacillus plantarum GKM3 ( Lactobacillus plantarum ) BCRC 910787, benzyl alcohol (8 wt%) as a preservative, glycerin (7 wt%) as a diluent, and Sucrose (10 wt%) was mixed thoroughly, dissolved in pure water (55 wt%), and stored at 4°C for later use. The aforementioned wt% refers to the ratio of each component to the total weight of the composition.

Composition 4: replace the bacteria powder of Lactobacillus plantarum GKM3 ( Lactobacillus plantarum ) BCRC 910787 in composition 4 with the bacteria powder of Lactobacillus fermentum GKF3 ( Lactobacillus fermentum ) BCRC 910824 (20 wt%), and the rest of the composition is the same as that of composition 3 .

none

Figure 1 shows the flow of animal experiments. The "pregnancy", "lactation" and "delivery" marked on the upper end of the horizontal axis in the figure refer to the state or period of the pup or its mother, and "d" refers to the number of days in the state or period. The double-arrowed line parallel to the horizontal axis in the figure indicates the period during which the test substance was administered. "OVA/CFA" and "sacrifice" marked at the lower end of the horizontal axis in the figure refer to the experimental steps taken on the young mice.

Figure 2 shows the concentration of IgG in serum of young mice after the sacrifice of five groups of young mice in the control group and the experimental group.

Figure 3 shows the concentration of IgA in the serum of young mice after the sacrifice of five groups of young mice in the control group and the experimental group.

Bifidobacterium lactis GKK2 ( Bifidobacterium lactis ) BCRC 910826

Lactobacillus rhamnosus GKLC1 ( Lactobacillus rhamnosus ) BCRC 910828

Lactobacillus plantarum GKM3 ( Lactobacillus plantarum ) BCRC 910787

Lactobacillus fermentum GKF3 ( Lactobacillus fermentum ) BCRC 910824

Claims (15)

An application for preparing a composition for enhancing immunity, wherein the composition comprises a lactic acid bacterium cell or its active substance, wherein the lactic acid bacterium is selected from Bifidobacterium lactis , Lactobacillus rhamnosus ), Lactobacillus plantarum ( Lactobacillus plantarum ) and Lactobacillus fermentum ( Lactobacillus fermentum ) constitute one or a combination; wherein the Bifidobacterium lactis GKK2 is BCRC 910826, Lactobacillus rhamnosus GKLC1 is BCRC 910828, Lactobacillus plantarum GKM3 with BCRC 910787 or Lactobacillus fermentum GKF3 with BCRC 910824 is deposited at the Bioresource Research Center of the Institute of Food Industry Development; wherein the composition is administered to a mother as a subject in an effective amount. The use as described in claim 1, wherein the composition is administered during pregnancy or breastfeeding of the mother. The use as described in claim 1, wherein the immunity refers to the immunity of a daughter of the mother. The use as described in claim 3, wherein the immunity refers to the immunity of the offspring in the period of fetus, newborn, infant or young child. The use as described in claim 3, wherein the immunity refers to the concentration of immunoglobulin in the serum of the progeny. The use as described in claim 3, wherein the boosting of immunity means that the concentration of immunoglobulin in the serum of the offspring whose mother has been given the composition is higher than that of offspring whose mother has not given the composition. The use as described in claim 5, wherein the immunoglobulin (Ig) is IgG or IgA. Use as described in claim 1, wherein the active substances of these lactic acid bacteria are prepared by the following method: (a) inoculate the bacterium of the lactic acid bacteria in a solid-state medium for solid-state culture to form a colony; (b) inoculate the colony (colony) cultivated in step (a) in a liquid medium for liquid culture to obtain a liquid medium containing the bacterium; (c) inoculating the liquid culture medium containing bacteria in step (b) in a fermenter for liquid amplification to obtain bacterial liquid; (d) centrifuging the bacterial liquid in step (c) to obtain bacterial sludge; (e) inoculating step (d) ) the bacteria slime is freeze-dried as bacteria powder; and (f) extracting the bacteria powder in step (e) with an alcohol as a solvent to obtain an alcohol extract. The use as described in claim 8, wherein the freeze-drying temperature is -196 to -40°C. The use as described in claim 8, wherein the alcohols are methanol, ethanol, isopropanol or a combination thereof. The use as described in claim 8, wherein the amount of the alcohols added is about 9 to 11 times the volume of the bacterial powder. The use as described in Claim 8, wherein the extraction is ultrasonic vibration extraction for about 0.5 to 1.5 hours. The use according to claim 1, wherein the composition comprises an additive selected from the following group: excipient, preservative, diluent, filler, absorption enhancer, sweetener or a combination thereof. The use as described in Claim 1, wherein the composition is a medicine, feed, beverage, nutritional supplement, dairy product, food or health food. The use as described in Claim 1, wherein the composition is in the form of powder, lozenge, suppository, microcapsule, ampoule, liquid spray or suppository.

Images